Skip to main content

Johnson & Johnson Could Have 100 Million COVID-19 Vaccines By April, Board Member McClellan Says

Johnson & Johnson is on track to analyze data from its late-stage single-dose COVID-19 vaccine trial.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.